Experimental pill promises new hope for deadly pancreatic cancer

A novel pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a study of 500 patients. The drug, which targets a mutated protein common in pancreatic cancer, showed fewer severe side effects and is being considered a new standard of care. The FDA plans to expedite its review, and the Food and Drug Administration is allowing expanded access for eligible patients.